family with sequence similarity 168 member AGenealiases: KIAA0280 · TCRP1
Q-omics provides the consensus-scored FAM168A profile across patient tissues and cancer cell-line models. FAM168A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM168A is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, FAM168A protein abundance shows 25,931 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where FAM168A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM168A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM168A survival associations across molecular data types. FAM168A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM168A RNA expression–survival associations across cancer types. High FAM168A expression shows unfavorable associations in ACC, BLCA and LIHC, but favorable associations in KIRC, UCS and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM168A RNA expression.
This table summarizes FAM168A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM168A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM168A shows lower tumor expression in BLCA and higher tumor expression in HNSC, LIHC, CHOL, LUSC and STAD. The HNSC box plot shows higher FAM168A RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with FAM168A in patient tissues and cancer cell lines. In patient samples, FAM168A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM168A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
